Skip to main content

Deal Alert: KKR invests $200-M in Gland Pharma

Gland Pharma Limited ("Company" or "Gland Pharma"), a leading Indian pure-play generic injectable pharmaceutical products company, today announced an agreement under which KKR, a leading global investment firm, will acquire a minority stake in the Company for approximately US$200 million, including KKR's acquisition of the entire stake held by Evolvence India Life Sciences Fund ("EILSF"), an existing private equity investor in Gland Pharma. 

Established in 1978 and based in Hyderabad, Gland Pharma develops and manufactures generic injectables primarily for the US market, and also for India and other semi-regulated markets. In 2003, Gland Pharma was the first company in India to get US Food and Drug Administration (FDA) approval for pharmaceutical liquid injectable products. Gland Pharma has also pioneered pre-filled syringe technology in India and exports products in this format to the US market. Having pioneered Heparin technology in India, Gland Pharma has a strong position in the US market for that product through its marketing partner. 

Gland Pharma Founder-Chairman P V N Raju said, "Gland Pharma is at an important juncture in its evolution where we have proven our sterile manufacturing capabilities, established ourselves as a high-quality manufacturer of complicated injectables products and achieved a track-record of strong financial performance. Our partnership with KKR will help us in our next phase of growth as we look to materially expand our manufacturing capacities and invest more in our development work with the goal of expanding our product registrations." P V N Raju also said, "We thank the Vetter family of Ravensburg, Germany, who are investors in Gland Pharma, for inspiring Gland Pharma in the niche field of pre-filled syringes. Vetter Pharma, owned by the Vetter family, enjoys a pre-eminent position globally in the field of pre-filled syringe technology." 

Gland Pharma Vice Chairman and Managing Director Dr. Ravi Penmetsa added, "We are very excited about the Company's future given our strong pipeline of innovative injectable products that are awaiting FDA approval. In addition to securing growth capital, we look forward to leveraging KKR's global network of relationships to help enter new markets." Dr. Ravi also said, "We wish to thank Evolvence India Life Sciences Fund for its contribution in positioning the Company on an impressive growth trajectory, aided in particular by the team's pro-active engagement with the Company in addition to the capital invested." 

Commenting on the agreement, KKR India Chief Executive Sanjay Nayar said, "Gland Pharma has a track record of strong financial performance as well as long-standing relationships with Indian and international pharmaceutical companies and we believe there is significant potential for it to grow these partnerships even further. We are excited to invest behind a high-quality promoter family and management team led by Dr. Ravi. We look forward to working closely with them to help build out the business and create value for all stakeholders." 

KKR's investment in Gland Pharma represents its fourth announced investment from the KKR Asian II Fund and its second overall private equity investment in India in 2013. The transaction is subject to regulatory approvals and other customary closing conditions.

About Gland Pharma

Established in 1978, Gland Pharma is a research-focused organization continuously developing niche products for the Indian and global pharmaceutical markets. It has pioneered Heparin technology in India and has a position of leadership in the GlycosAminoGlycans (GAGs) range of molecules. The company manufactures Active Pharmaceutical Ingredients (APIs) and injectable formulations for niche segments such as Osteoarthritis, Anti-coagulants, Gynaecology, and Ophthalmology. For further information, please visit the company's website at http://www.glandpharma.com/ 

About KKR

Founded in 1976 and led by Henry Kravis and George Roberts, KKR is a leading global investment firm with $90.2 billion in assets under management as of September 30, 2013. KKR manages assets through a variety of investment funds and accounts covering multiple asset classes. KKR & Co. L.P. is publicly traded on the New York Stock Exchange (NYSE: KKR). KKR has a more than 20-year track record of healthcare investing around the world, including investments in HCA, Accellent, Ambea, Biomet, China Cord Blood Corporation, Genesis Care, Jazz Pharmaceuticals and PRA International. Most recently, KKR has announced its plan to invest in Panasonic Healthcare (Japan). The firm has invested more than US$1 billion in private equity in India since 2006. 

Venture Intelligence is the leading provider of data and analysis on Private Company Financials, Transactions (private equity, venture capital and M&A) & their Valuations in India. Click Here to view our products list including the Free Deal Digest Weekly: India's First & Most Exhaustive Transactions Newsletter.

Popular posts from this blog

VC Interview: Shailendra Singh of Sequoia Capital India

In a recent interview to Venture Intelligence, Shailendra Singh discussed some of the firm’s newer investments in the early stage segment including in the online payments space, the progress at a few existing portfolio companies and the active role the firm is playing in helping its portfolio companies scale and succeed in India and globally. Prior to joining the firm in 2006, Singh was a strategy consultant at Bain & Company in New York and before that, an entrepreneur in the digital media industry.

Venture Intelligence: How does Sequoia go about identifying potential early stage investments in India? Is there anything different you are doing today than, say, a couple of years back?

Shailendra Singh: There is a lot more focus on technology investing and early stage investing. In general, as you might remember a few years ago, we were doing primarily growth investing but in the past 18-odd months, we have had a very strong focus on early stage and that’s continuing. In terms of how…

KPMG Tops League Table for Financial Advisor to Private Equity Transactions in H1 2018

The transaction advisory unit of KPMG claimed the top position in the Venture Intelligence League Table for Transaction Advisor to Private Equity deals in the first half of 2018, advising deals worth $1.7 Billion. KPMG acted as the financial advisor to NHAI in the $1.5 Billion investment by Macquarie to operate 9 highway projects under the toll-operate-transfer (TOT) model. Ernst &  Young (which advised the $730 million asset sale by Indiabulls Real Estate to Blackstone) and Kotak (which advised the Vishal Megamart - Partners Group deal) accounted for the second and third spots respectively.
The Venture Intelligence League Tables, the first such initiative exclusively tracking transactions involving India-based companies, are based on value of PE and M&A transactions advised by Transaction and Legal Advisory firms.
Arpwood Capital (which advised the $760 million investment by Temasek in the $2.1 Billion Schneider Electric buyout of L&;T Electrical and Automation business) …

SAIF, Kedaara Capital bag 2 awards each at Venture Intelligence APEX’18 PE-VC Awards

Mumbai, India, March 6, 2013: Kedaara Capital and SAIF Partners bagged two awards each as part of the Venture Intelligence “Awards for Private Equity Excellence” (APEX)event organized by Venture Intelligence. SAIF Partners bagged the VC Exit of the Year – 2017 Award (for the part exit from Paytm/One97 Communications) and the New Fund Raise of the Year – Venture Capital - 2017 Award. Kedaara Capital won the Best Private Equity Firm – Special Situations – 2017 the New Fund Raise of the Year – Private Equity - 2017.
The event opened with a Fireside Chat with V Vaidyanathan, Founder & Executive Chairman, Capital First interviewed by Sesh A.V, Managing Director, Basiz Fund Services

Snapshots of the awards ceremony:

Sesh AV, Managing Director, Basiz Fund Services presents the Venture Capital Investment of the Year award to Ramesh Radhakrishnan, Partner, Artiman Ventures.

Nagaraja Prakasam, Board Member, Sattva Consulting presents the Impact Investor of the Year award to Varun Saini, Progr…